BR112017022691A2 - inibidor de bromodomínio. - Google Patents
inibidor de bromodomínio.Info
- Publication number
- BR112017022691A2 BR112017022691A2 BR112017022691-0A BR112017022691A BR112017022691A2 BR 112017022691 A2 BR112017022691 A2 BR 112017022691A2 BR 112017022691 A BR112017022691 A BR 112017022691A BR 112017022691 A2 BR112017022691 A2 BR 112017022691A2
- Authority
- BR
- Brazil
- Prior art keywords
- bromodomain inhibitor
- bromodomain
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562151205P | 2015-04-22 | 2015-04-22 | |
US62/151,205 | 2015-04-22 | ||
PCT/US2016/029029 WO2016172618A1 (en) | 2015-04-22 | 2016-04-22 | Bromodomain inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017022691A2 true BR112017022691A2 (pt) | 2018-07-17 |
Family
ID=57143581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017022691-0A BR112017022691A2 (pt) | 2015-04-22 | 2016-04-22 | inibidor de bromodomínio. |
Country Status (23)
Country | Link |
---|---|
US (1) | US20160310423A1 (pt) |
EP (1) | EP3285770A4 (pt) |
JP (1) | JP2018513863A (pt) |
KR (1) | KR20170139119A (pt) |
CN (1) | CN107613981A (pt) |
AR (1) | AR104340A1 (pt) |
AU (1) | AU2016252992A1 (pt) |
BR (1) | BR112017022691A2 (pt) |
CA (1) | CA2983446C (pt) |
CL (1) | CL2017002679A1 (pt) |
CO (1) | CO2017011482A2 (pt) |
EA (1) | EA201792317A1 (pt) |
EC (1) | ECSP17071545A (pt) |
HK (1) | HK1243948A1 (pt) |
IL (1) | IL255120B (pt) |
MX (2) | MX2020010899A (pt) |
NZ (1) | NZ736630A (pt) |
PE (1) | PE20180036A1 (pt) |
PH (1) | PH12017501933A1 (pt) |
SG (1) | SG11201708627TA (pt) |
TW (1) | TW201642860A (pt) |
WO (1) | WO2016172618A1 (pt) |
ZA (1) | ZA201707186B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
WO2018075796A1 (en) * | 2016-10-20 | 2018-04-26 | Celgene Quanticel Research, Inc | Bromodomain inhibitor |
DK3532059T3 (da) | 2016-10-27 | 2022-03-14 | Celgene Quanticel Res Inc | Kombinationsterapi med bromdomæne- og ekstraterminal proteinhæmmer |
EP3826992A2 (en) * | 2018-07-23 | 2021-06-02 | Celgene Quanticel Research, Inc. | Process for the preparation of bromodomain inhibitor |
CN117136057A (zh) * | 2021-02-22 | 2023-11-28 | 赛尔基因昆蒂赛尔研究公司 | 用于治疗***癌的溴结构域(bet)抑制剂 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
FI3640241T3 (fi) * | 2013-10-18 | 2023-01-13 | Bromodomeeni-inhibiittorit | |
WO2018075796A1 (en) * | 2016-10-20 | 2018-04-26 | Celgene Quanticel Research, Inc | Bromodomain inhibitor |
-
2016
- 2016-04-19 TW TW105112168A patent/TW201642860A/zh unknown
- 2016-04-21 AR ARP160101100A patent/AR104340A1/es unknown
- 2016-04-22 MX MX2020010899A patent/MX2020010899A/es unknown
- 2016-04-22 EP EP16784024.8A patent/EP3285770A4/en not_active Withdrawn
- 2016-04-22 CN CN201680032770.1A patent/CN107613981A/zh active Pending
- 2016-04-22 PE PE2017002306A patent/PE20180036A1/es not_active Application Discontinuation
- 2016-04-22 CA CA2983446A patent/CA2983446C/en active Active
- 2016-04-22 WO PCT/US2016/029029 patent/WO2016172618A1/en active Application Filing
- 2016-04-22 JP JP2017554566A patent/JP2018513863A/ja active Pending
- 2016-04-22 SG SG11201708627TA patent/SG11201708627TA/en unknown
- 2016-04-22 BR BR112017022691-0A patent/BR112017022691A2/pt not_active Application Discontinuation
- 2016-04-22 AU AU2016252992A patent/AU2016252992A1/en not_active Abandoned
- 2016-04-22 MX MX2017013501A patent/MX2017013501A/es active IP Right Grant
- 2016-04-22 KR KR1020177033575A patent/KR20170139119A/ko not_active Application Discontinuation
- 2016-04-22 NZ NZ736630A patent/NZ736630A/en unknown
- 2016-04-22 EA EA201792317A patent/EA201792317A1/ru unknown
- 2016-04-22 US US15/136,761 patent/US20160310423A1/en not_active Abandoned
-
2017
- 2017-10-18 IL IL255120A patent/IL255120B/en active IP Right Grant
- 2017-10-20 CL CL2017002679A patent/CL2017002679A1/es unknown
- 2017-10-23 PH PH12017501933A patent/PH12017501933A1/en unknown
- 2017-10-23 ZA ZA2017/07186A patent/ZA201707186B/en unknown
- 2017-10-26 EC ECIEPI201771545A patent/ECSP17071545A/es unknown
- 2017-11-08 CO CONC2017/0011482A patent/CO2017011482A2/es unknown
-
2018
- 2018-03-14 HK HK18103550.6A patent/HK1243948A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PH12017501933A1 (en) | 2018-03-19 |
EP3285770A4 (en) | 2018-10-31 |
ECSP17071545A (es) | 2017-12-01 |
US20160310423A1 (en) | 2016-10-27 |
AU2016252992A1 (en) | 2017-11-09 |
CA2983446A1 (en) | 2016-10-27 |
CO2017011482A2 (es) | 2018-01-31 |
MX2017013501A (es) | 2018-02-09 |
CN107613981A (zh) | 2018-01-19 |
JP2018513863A (ja) | 2018-05-31 |
EP3285770A1 (en) | 2018-02-28 |
CA2983446C (en) | 2024-04-09 |
IL255120B (en) | 2021-03-25 |
ZA201707186B (en) | 2019-01-30 |
WO2016172618A1 (en) | 2016-10-27 |
IL255120A0 (en) | 2017-12-31 |
MX2020010899A (es) | 2022-02-15 |
SG11201708627TA (en) | 2017-11-29 |
TW201642860A (zh) | 2016-12-16 |
PE20180036A1 (es) | 2018-01-09 |
CL2017002679A1 (es) | 2018-05-25 |
KR20170139119A (ko) | 2017-12-18 |
HK1243948A1 (zh) | 2018-07-27 |
AR104340A1 (es) | 2017-07-12 |
EA201792317A1 (ru) | 2018-03-30 |
NZ736630A (en) | 2024-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FIC20230006I1 (fi) | Vutrisiraani | |
DK3627029T3 (da) | Manipulationssikret låg | |
DK3283625T3 (da) | Nukleasemedieret genomeditering | |
MA52814A (fr) | Inhibiteurs de bromodomaine | |
DK3331869T3 (da) | Muscarinagonister | |
DK3305788T3 (da) | Janus-kinase-hæmmer | |
FR3039337B1 (fr) | Motoreducteur compact | |
DK3277719T3 (da) | Polypeptider | |
DK3360890T3 (da) | Genterapi | |
DK3331528T3 (da) | Muskarinagonister | |
DK3253762T3 (da) | 9h-pyrrolo-dipyridinderivater. | |
DK3310450T3 (da) | Olie-vand-separator | |
DK3331529T3 (da) | Muskarinagonister | |
MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
BR112017022691A2 (pt) | inibidor de bromodomínio. | |
DK3270930T3 (da) | Præeklampsi | |
MA46280A (fr) | Inhibiteurs de la dopamine-b-hydroxylase | |
KR20180084876A (ko) | 내플라즈마성 부재 | |
DK3394281T3 (da) | Gærcelle | |
DK3292136T3 (da) | Penicillin-g-acylaser | |
IT201600084952A1 (it) | Coglifrutta. | |
ES1150114Y (es) | Abarcón. | |
DE112015006486A5 (de) | Inkubationsrinne | |
DK3318308T3 (da) | Badmintonketsjer | |
DK3274482T3 (da) | Stenborsknop |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |